Therapeutic Mechanisms of Epidural Spinal Cord Stimulation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05556902 |
Recruitment Status :
Recruiting
First Posted : September 27, 2022
Last Update Posted : April 16, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Blood Pressure Low Back Pain Hypertension | Device: Permanent Epidural Spinal Cord Stimulation | Not Applicable |
The purpose of this study in patients undergoing routine care epidural spinal cord stimulation (SCS) is to determine 1) whether SCS reduces arterial blood pressure (BP) in patients which chronic low back pain and hypertension, 2) whether higher baseline BP (i.e., hypertension) predicts reductions in pain following SCS, and finally 3) whether different SCS waveforms elicits stimulus-evoked compound action potentials (ECAPs) in spinal cord and at the cortex (electroencephalography, and magnetoenchphalography).
The Investigators will identify patients with chronic pain who are scheduled for SCS implant at the University of Alabama at Birmingham for management of chronic neuropathic pain as part of routine care. The research team will assess BP with an arm cuff arm cuff before and after the implant among patients providing written informed consent.
The Investigators' central clinical hypothesis is that SCS decreases blood pressure in patients with chronic pain and comorbid hypertension. The Investigators further hypothesize that the SCS will improve serological markers of sympathetic nerve activity and kidney function, possibly due to reductions in spinal cord sympathetic nerve activity. A secondary hypothesis is that higher baseline blood pressure predicts larger reductions in blood pressure following SCS implant.
Additionally, this project seeks to expand knowledge on therapeutic mechanisms of SCS via recording electrophysiological responses at the spinal cord (via adjacent, unused SCS contacts) and from EEG scalp recordings over the cerebral cortex.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Therapeutic Mechanisms of Epidural Spinal Cord Stimulation |
Actual Study Start Date : | August 2, 2022 |
Estimated Primary Completion Date : | May 1, 2024 |
Estimated Study Completion Date : | May 1, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment
Patients that proceed with permanent implantation of a spinal cord stimulator.
|
Device: Permanent Epidural Spinal Cord Stimulation
Permanent Spinal Cord Stimulation implanted in participants undergoing routine care for management of chronic neuropathic pain. |
No Intervention: Control
Patients who do not proceed with permanent implantation of a spinal cord stimulator.
|
- Arterial Blood Pressure Change [ Time Frame: Baseline (1 week pre-op) ]The research team will assess systolic and diastolic blood pressure with an arm cuff.
- Arterial Blood Pressure Change [ Time Frame: Visit 2 (4-6 weeks post-op) ]The research team will assess systolic and diastolic blood pressure with an arm cuff.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 89 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or Female, age 18-89
- Chronic pain for more than 3 months
- Willing to visit a research lab
- Willing to undergo a blood draw
- Able to provide written informed consent
Exclusion Criteria
- History of neurological disease (e.g., dementias, Parkinson's)
- History of stroke
- Current diagnosis of cancer
- Subject is unwilling or unable to comply with the protocol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05556902
Contact: Chris Gonzalez, MS | (205) 975-3732 | clgonzalez@uabmc.edu |
United States, Alabama | |
University of Alabama at Birmingham | Recruiting |
Birmingham, Alabama, United States, 35233 | |
Contact: Marshall Holland, MD 205-934-2654 mtholland@uabmc.edu |
Principal Investigator: | Marshall Holland, MD | The University of Alabama at Birmingham |
Responsible Party: | Marshall Holland, Assistant Professor, University of Alabama at Birmingham |
ClinicalTrials.gov Identifier: | NCT05556902 |
Other Study ID Numbers: |
IRB-300009200 UAB ( Other Identifier: UAB ) |
First Posted: | September 27, 2022 Key Record Dates |
Last Update Posted: | April 16, 2024 |
Last Verified: | April 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Spinal Cord Stimulation Epidural Spinal Cord Stimulation SCS Arterial Blood Pressure |
Low Back Pain Back Pain Pain Neurologic Manifestations |